Lab Report
Scientific Report 2010 Ryan (215.39 kB)
Key Publications
Vousden KH, Ryan KM (2009). p53 and metabolism. Nat Rev Cancer 9, 691-700.
Wilkinson S, O'Prey J, Fricker M, Ryan KM (2009). Hypoxia-selective
macroautophagy and cell survival signaled by autocrine PDGFR activity.
Genes Dev 23, 1283-8.
O'Prey J, Skommer J, Wilkinson S, Ryan KM (2009). Analysis of DRAM-related
proteins reveals evolutionarily conserved and divergent roles in the
control of autophagy. Cell Cycle 8, 2260-5.
Bell HS, Ryan KM (2008). iASPP inhibition: increased options in
targeting the p53 family for cancer therapy. Cancer Res. 68, 4959-62.
Crighton D, O’Prey J, Bell HS, Ryan KM (2007). p73 regulates DRAM- independent autophagy that does not contribute to programmed cell death. Cell Death & Differ. 14, 1071-9.
Bell HS, Dufes C, O’Prey J, Crighton D, Bergamaschi D, Lu X, Schätzlein AG, Vousden KH, Ryan KM (2007). A novel p53-derived apoptotic peptide de-represses p73 to cause tumor regression in vivo. J Clin Invest. 117, 1008-18.
Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM (2006). DRAM – a p53- induced modulator of autophagy is critical for apoptosis. Cell 126, 121-34.
Biography
Education and qualifications
1996: PhD, Beatson Institute for Cancer Research (University of Glasgow), Supervisor George Birnie
1991: BSc, Biochemistry (Honours), University of Liverpool
Appointments
2007-present: Professor of Molecular Cell Biology, University of Glasgow
2007-present: Senior Group Leader, Beatson Institute for Cancer Research
2002-2008: Cancer Research UK Senior Cancer Research Fellow
2001-2007: Junior Group Leader, Beatson Institute for Cancer Research
1996-2001: Postdoctoral fellow with Karen Vousden, National Cancer Institute, Frederick, USA
Honours and awards
Tenovus Medal, 2012
Cancer Researcher Award, European Association for Cancer Research, 2010
Elected Fellow of the Society of Biology, 2009
Certificate of Merit, European Association for Cancer Research, 2002
Cancer Research UK Senior Cancer Research Fellowship, 2002
National Institutes of Health Year 2001 Fellows Award for Research Excellence, 2000
National Institutes of Health Year 2000 Fellows Award for Research Excellence, 1999
Recent Publications
2011
Wilkinson S, Croft DR, O'Prey J, Meedendorp A, O'Prey M, Dufes C, Ryan KM (2011). The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy. Autophagy 7.
[Epub ahead of print].
Rosenfeldt MT, Ryan KM (2011). The multiple roles of autophagy in cancer. Carcinogenesis 32, 955-63.
2010
Fricker M, O'Prey J, Tolkovsky AM, Ryan KM (2010).
Phosphorylation of Puma modulates its apoptotic
function by regulating protein stability. Cell Death Dis.
1, e59.
Helgason GV, O'Prey J, Ryan KM (2010).
Oncogene-induced sensitization to chemotherapyinduced
death requires induction as well as
deregulation of E2F1. Cancer Res. 70, 4074-80.
O'Prey J, Crighton D, Martin AG, Vousden KH,
Fearnhead HO, Ryan KM (2010).
p53-mediated induction of Noxa and p53AIP1
requires NFkappaB. Cell Cycle 9, 947-52.
Bennett H, Fleming J, O’Prey J, Ryan KM, Leung H (2010).
Androgens modulate autophagy and cell death via
regulation of the ER chaperone Grp78/BiP in
prostate cancer cells. Cell Death Dis. 1, e72.
Croft DR, Crighton D, Samuel MS, Lourenco FC, Munro J, Wood J, Bensaad K, Vousden KH, Sansom OJ, Ryan KM, Olson MF (2010). p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival. Cell Res. 21, 666-82.
Long JS, Ryan KM (2010).
p53 and senescence: a little goes a long way. Cell
Cycle 9, 4050-1.
Lorin S, Pierron G, Ryan KM, Codogno P,
Djavaheri-Mergny M (2010).
Evidence for the interplay between JNK and
p53-DRAM signalling pathways in the regulation
of autophagy. Autophagy 6, 153-4.
Ryan KM (2010).
Cancer: Viruses' backup plan. Nature 466,
1054-5.
Ryan KM (2010).
p53 and autophagy in cancer: guardian of the
genome meets guardian of the proteome. Eur J
Cancer 47, 44-50.
Wilkinson S, Ryan KM (2010).
Autophagy: an adaptable modifier of
tumourigenesis. Curr Opin Genet Dev. 20,
57-64.
2009
Lorin S, Borges A, Dos Santos L, Souquère S, Pierron G, Ryan KM, Codogno P, Djavaheri-Mergny M (2009). JNK activation is essential for Dram-dependent induction of autophagy and apoptosis in 2-Methoxyestradiol treated Ewing sarcoma cells. Cancer Res. 69, 6924-31.
Wilkinson S, Ryan KM (2009). Growth factor signalling permits hypoxia-induced autophagy by a HIF1α-dependent, BNIP3/3L-independent transcriptional program in human cancer cells. Autophagy 5, 1068-9.
Huser CA, Pringle MA, Heath V, Bell AK, Kendrick H, Smalley M, Crighton D, Ryan KM, Gusterson BA, Stein T (2010). TCS-22D1 isoforms have opposing roles in mammary epithelial cell survival. Cell Death & Differ. 17, 304-15.
Vousden KH, Ryan KM (2009). p53 and metabolism. Nat Rev Cancer 9, 691-700.
Lorin S, Pierron G, Ryan KM, Codogno P, Djavaheri-Mergny M (2010). Evidence for the interplay between JNK and p53-DRAM signalling pathways in the regulation of autophagy. Autophagy 6, 153-4.
Rosenfeldt MT, Ryan KM (2009). The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med.11, e36.
O’Prey J, Crighton D, Martin AG, Vousden KH, Fearnhead HO, Ryan KM (2010). p53-mediated induction of Noxa and p53AIP1 requires NF-kB. Cell Cycle, In press
Wilkinson S, Ryan KM (2010). Autophagy: an adaptive modifier of tumourigenesis. Curr Opin Genet Dev., Epub 15 Jan 2010
O'Prey J, Skommer J, Wilkinson S, Ryan KM (2009). Analysis of DRAM-related proteins reveals evolutionarily conserved and divergent roles in the control of autophagy. Cell Cycle 8, 2260-5.
Wilkinson S, O'Prey J, Fricker M, Ryan KM (2009). Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev. 23, 1283-8.
Martin AG, Trama J, Crighton D, Ryan KM, Fearnhead HO (2009). Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B. Aging 1, 335-49.
Yee KS, Wilkinson S, James J, Ryan KM, Vousden KH (2009). PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 16, 1135-45
2008
O’Prey J, Wilkinson S, Ryan KM (2008). Tumor antigen LRRC15 impedes adenoviral infection – implications for viral based cancer therapy. J Virol. 82, 5933-9.
Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P (2008). Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 7, 1648-62.
Bell HS, Ryan KM (2008). iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res. 68, 4959-62.
Klionsky DJ
et al. (2008). Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4, 1-25.
2007
Bell HS, Dufes C, O’Prey J, Crighton D, Bergamaschi D, Lu X, Schätzlein AG, Vousden KH, Ryan KM (2007). A novel p53-derived apoptotic peptide de-represses p73 to cause tumor regression in vivo. J Clin Invest. 117, 1008-18.
Crighton D, O’Prey J, Bell HS, Ryan KM (2007). p73 regulates DRAM- independent autophagy that does not contribute to programmed cell death. Cell Death & Differ. 14, 1071-9.
Bell HS, Ryan KM (2007). Targeting the p53 family for cancer therapy – ‘Big Brother’ joins the fight. Cell Cycle 6, 1995-2000.
Crighton D, Wilkinson S, Ryan KM (2007). DRAM links autophagy to p53 and programmed cell death. Autophagy 3, 72-4.
Ewings KE, Ryan KM (2007). Hzf and hCAS/CSE1L: making the right choice in p53-mediated tumour suppression. Cell Res. 17, 829-31.
The aim of our group is to understand the factors regulating programmed cell death in cancer cells. Since it is known that inhibition of cell death mechanisms is a common event in tumour development, this poses problems for many forms of chemotherapy that utilise cell death pathways, leading to drug resistance. 
